The new entity will leverage TriNetX's LIVE platform, which encompasses a network of 200 million patient records.

TriNetX, a global leader in real-world data (RWD) and real-world evidence (RWE) solutions, has partnered with Fujitsu, a ...

Patients receiving an immune checkpoint inhibitor for a neoplasm face an increased risk for rheumatoid arthritis, an ...

For older adults with inflammatory bowel disease (IBD), there was no significant difference in the risk of major ...

Although Stelara and Entyvio demonstrated similar cardiovascular safety profiles among older patients with inflammatory bowel ...

A newly released economic impact analysis conducted by the Connecticut Center for Economic Analysis (CCEA) at the University of Connecticut and jointly commissioned by Connecticut Sports Group and ...

Pathify, a leading digital engagement hub for higher education, today announced it has raised $25 million in a minority investment from Five Elms Capital, a leading software investment ...

No significant difference in the risk for MACE was observed between patients with IBD receiving JAK vs TNF inhibitors.

Persistent care barriers may lead patients with inflammatory bowel disease (IBD) to ration medication or skip doses. The ...

Women prescribed a GLP-1 receptor agonist up to 2 years before conception were less likely to develop hypertensive disorders of pregnancy, gestational diabetes, have a preterm birth or cesarean ...

Patients with Klinefelter and triple X syndromes show an increased prevalence of SLE and Sjögren disease, likely due to the synergistic interaction of the extra X chromosomes.